No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MLTX250117P75000
- 0.00
- 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest75.00Strike Price0.00Turnover0.00%IV-61.93%PremiumJan 17, 2025Expiry Date28.69Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.63Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
MoonLake Analyst Ratings
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $81
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Accolade (ACCD)
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62
MoonLake Immunotherapeutics Poised for Transformational Growth: Buy Rating Affirmed on Strategic Clinical Expansion and Strong Financial Position